BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19368417)

  • 1. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
    Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
    Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
    Corren J; Korenblat PE; Miller CJ; O'Brien CD; Mezzanotte WS
    Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease.
    Lyseng-Williamson KA
    Drugs; 2009 Jul; 69(11):1459-70. PubMed ID: 19634924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.
    Korenblat PE; Rosenwasser LJ
    Allergy Asthma Proc; 2010; 31(3):190-202. PubMed ID: 20482961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.
    Morice AH; Hochmuth L; Ekelund J; Thorén A; Puterman AS
    Pulm Pharmacol Ther; 2008; 21(1):32-9. PubMed ID: 17118686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
    Kerwin EM; Oppenheimer JJ; LaForce C; Parasuraman B; Miller CJ; O'Dowd L; Goldman M
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma.
    Morice AH; Peterson S; Beckman O; Osmanliev D
    Int J Clin Pract; 2007 Nov; 61(11):1874-83. PubMed ID: 17887990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ; Senn S; Mezzanotte WS
    Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide.
    Berger WE; Gillen M; Eckerwall G; Uryniak T; Trudo FJ; Lampl KL
    Allergy Asthma Proc; 2014; 35(2):134-40. PubMed ID: 24717790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma.
    Murphy K; Nelson H; Parasuraman B; Boggs R; Miller C; O'Dowd L
    Curr Med Res Opin; 2008 Mar; 24(3):879-94. PubMed ID: 18267051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler.
    Chervinsky P; Baker J; Bensch G; Parasuraman B; Boggs R; Martin P; O'Dowd L
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):463-73. PubMed ID: 19055199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.